Showing results (51-60 of 295) with videos related to
Sort By:
Pageof 30
NAR Cancer|March 16, 2026
Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cellsJennifer R Tall, Robert Te Poele, Alexandra Vasile, et al.Oncotarget|January 29, 2016
Blocking the survival of the nastiest by HSP90 inhibitionPaul Workman, Paul A Clarke, Bissan Al-LazikaniFuture Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-LazikaniExpert Opinion on Emerging Drugs|May 25, 2004
Histone modification enzymes: novel targets for cancer drugsRebecca Kristeleit, Lindsay Stimson, Paul Workman, et al.Annals of the New York Academy of Sciences|May 22, 2007
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressPaul Workman, Francis Burrows, Len Neckers, et al.Drug Discovery Today|December 26, 2021
Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patientsRichard Hoey, Eva Sharpe, Angela Kukula, et al.Cell Cycle (Georgetown, Tex.)|February 7, 2009
Death by chaperone: HSP90, HSP70 or both?Marissa V Powers, Paul A Clarke, Paul WorkmanCancer Cell|April 21, 2012
Personalized medicine: patient-predictive panel powerPaul Workman, Paul A Clarke, Bissan Al-LazikaniEuropean Journal of Cancer (Oxford, England : 1990)|November 16, 2004
Gene expression microarray technologies in the development of new therapeutic agentsPaul A Clarke, Robert te Poele, Paul WorkmanCurrent Opinion in Pharmacology|July 2, 2013
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncologyPaul Workman, Bissan Al-Lazikani, Paul A ClarkePageof 30